Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 5.14 -0.77% -0.04
BCRX closed down 0.77 percent on Wednesday, April 18, 2018, on 40 percent of normal volume.

Earnings due: May 3

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Apr 18 Overbought Stochastic Strength 0.00%
Apr 17 Crossed Above 50 DMA Bullish -0.77%
Apr 17 Golden Cross Bullish -0.77%
Apr 17 Upside 200 DMA Break Bullish -0.77%
Apr 17 180 Bullish Setup Bullish Swing Setup -0.77%
Apr 17 Wide Bands Range Expansion -0.77%
Apr 17 Overbought Stochastic Strength -0.77%
Apr 16 200 DMA Resistance Bearish 3.21%
Apr 16 Fell Below 50 DMA Bearish 3.21%
Apr 16 Narrow Range Bar Range Contraction 3.21%

Older signals for BCRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.39
52 Week Low 3.95
Average Volume 977,472
200-Day Moving Average 5.0248
50-Day Moving Average 5.0484
20-Day Moving Average 4.9675
10-Day Moving Average 4.92
Average True Range 0.2465
ADX 14.85
+DI 22.77
-DI 17.87
Chandelier Exit (Long, 3 ATRs ) 4.6705
Chandelier Exit (Short, 3 ATRs ) 5.2695
Upper Bollinger Band 5.4141
Lower Bollinger Band 4.5209
Percent B (%b) 0.69
BandWidth 17.980876
MACD Line -0.0099
MACD Signal Line -0.0477
MACD Histogram 0.0379
Fundamentals Value
Market Cap 413.4 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -8.29
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.38
Resistance 3 (R3) 5.40 5.34 5.34
Resistance 2 (R2) 5.34 5.28 5.33 5.33
Resistance 1 (R1) 5.24 5.24 5.21 5.22 5.31
Pivot Point 5.18 5.18 5.17 5.17 5.18
Support 1 (S1) 5.08 5.12 5.05 5.06 4.97
Support 2 (S2) 5.02 5.08 5.01 4.95
Support 3 (S3) 4.92 5.02 4.94
Support 4 (S4) 4.90